Tip: To match a phrase, use quotation marks around the search term. eg. "Parliamentary Estate"

Written Question
Insolvency: Fees and Charges
28 Jul 2021

Questioner: Lord Bishop of St Albans (Bishops - Bishops)

Question

To ask Her Majesty's Government, further to the report by Christians Against Poverty Shipshape or sinking ship?, published on 21 July, what plans they have to remove insolvency fees for individuals with insufficient surplus income.

Answered by Lord Callanan

There are no immediate plans to review the bankruptcy application or Debt Relief Order (DRO) fees. Where the fee is an issue, assistance is already available to allow a debtor to pay in instalments prior to the making of the bankruptcy order or DRO. In addition, some charities offer help with paying the fee.

The Government has announced that it will be conducting a review of the personal insolvency framework in due course to ensure that it continues to be fit for purpose.


Written Question
Coronavirus: Vaccination
9 Feb 2021

Questioner: Lord Bishop of St Albans (Bishops - Bishops)

Question

To ask Her Majesty's Government how many COVID-19 vaccination doses they have ordered in total; whether they intend to order more doses than the number required to vaccinate the population of the UK; and if so, what plans they have to ensure that any surplus doses are used effectively.

Answered by Lord Callanan

The UK Government has secured early access to 457 million vaccines doses through agreements with eight separate vaccine developers. This includes agreements with BioNTech/Pfizer, Oxford/AstraZeneca, GlaxoSmithKline and Sanofi Pasteur, Novavax, Janssen, Valneva and Moderna.

The Government continues to monitor the landscape of COVID-19 vaccine development, both here in the UK and internationally, and will keep the situation under review.

My Rt. Hon. Friend the Prime Minister has made clear that equitable access is an integral part of the UK’s approach to vaccine development and distribution. The UK is working with international partners to support vaccine development, manufacturing scale-up and future distribution to meet both domestic and international needs.